MSD has said it will cut $3 billion off its annual costs by the end of 2027 as it prepares for the end of patent protection for blockbuster cancer drug Keytruda the following year. The plan was ...

MSD is preparing to take on Takeda in the dengue fever vaccine market, moving its V181 candidate into phase 3.